The first results of using «3D» interferon-free therapy in real clinical practice in Russia: the experience of the Kirov Region
- Авторлар: Tikhomolova E.G1, Osokina A.A1, Matveev D.A2, Utemova E.D2, Kulikova N.V3, Fursova E.A1, Zhuikova V.I1
-
Мекемелер:
- Kirov Clinical Hospital for Infectious Diseases
- Ministry of Health of the Kirov Region
- Kirov Regional Territorial Compulsory Health Insurance Fund
- Шығарылым: № 3 (2016)
- Беттер: 77-82
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2226-6976/article/view/278447
- ID: 278447
Дәйексөз келтіру
Аннотация
Негізгі сөздер
Толық мәтін
Авторлар туралы
E. Tikhomolova
Kirov Clinical Hospital for Infectious Diseases
Email: e.tikhomolova@mail.ru. kikb43@rambler.ru
A. Osokina
Kirov Clinical Hospital for Infectious Diseases
Email: Allao08@mail.ru
D. Matveev
Ministry of Health of the Kirov Region
Email: matveev@ako.kirov.ru
Kirov
E. Utemova
Ministry of Health of the Kirov Region
Email: ip-depart@medstat.kirov.ru
Kirov
N. Kulikova
Kirov Regional Territorial Compulsory Health Insurance Fund
Email: kotfoms@kotfoms.kirov.ru
E. Fursova
Kirov Clinical Hospital for Infectious Diseases
Email: Kikb43@rambler.ru
V. Zhuikova
Kirov Clinical Hospital for Infectious Diseases
Email: kikb43@rambler.ru
Әдебиет тізімі
- Guidelines for the screening, care and treatment of persons with hepatitis C infection. http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/
- WHO Hepatitis C Fact sheet № 164. http://www.who.int/mediacen-tre/ factsheets/fs164/en/
- Freeman A.J., Dore G.J., Law M.G., Thorpe M., Von Overbeck J., Lloyd A.R., Marinos G., Kaldor J.M. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809-816 [PMID: 11584380 DOI: 10.1053/ jhep.2001.27831].
- Fried M.W. Side effects of therapy of hepatitis C and the irmanagement. Hepatology 2002; 36: 237-244.
- Sulkowski M.S., Cooper C., Hunyady B., Jia J., Ogurtsov P., Peck-Radosavljevic M., Shiffman M.L., Yurdaydin C., Dalgard O. Management of adverse effects of Peg-IFN and ribavirintherapy for hepatitis C. Nat. Rev. Gastroenterol. Hepatol. 2011; (8): 212-223.
- Noureddin M., Ghany M.G. Pharmacokinetics andpharmacodynamics of peginterferon and ribavirin:implications for clinical efficacy in the treatment of chronichepatitis C. Gastroenterol. Clin. North. Am. 2010; 39: 649-658.
- Reddy K.R., Nelson D.R., Zeuzem S. Ribavirin: current role in the optimal clinical management of chronic hepatitis C. J. Hepatol. 2009; 50: 402-411.
- Cooper C.L., Druyts E., Thorlund K., Nachega J.B., El Khoury A.C., O’Regan C., Mills E.J. Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis. Therapeutics and Clinical Risk Management 2012: (8); 105-130.
- Инструкция по применению боцепревира FDA. http://www. accessdata.fda.gov/drugsatfda_docs/label/2011/202258lbl.pdf
- Инструкция по применению телапревира FDA. http://www. accessdata.fda.gov/drugsatfda_docs/label/2011/201917lbl.pdf
- Zeuzem S., Andreone P., Pol S., Lawitz E, Diago M, Roberts S., Focaccia R., Younossi Z., Foster G.R., Horban A., Ferenci P., Nevens F., Müllhaupt B., Pockros P., Terg R., Shouval D., van Hoek B., Weiland O., Van Heeswijk R., De Meyer S., Luo D., Boogaerts G., Polo R., Picchio G., Beumont M.; REALIZE Study Team. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 2011; 364: 2417-2428. doi: 10.1056/NEJMoa1013086
- Vierling J.M., Helmond F.A., Wahl J. Sustained Virologic Response (SVR) in Prior Peginterferon/Ribavirin (PR) Treatment Failures After Retreatment With Boceprevir (BOC) PR: Final Results of the Provide Study. Digestive Disease Week (DDW 2013). Orlando, May 18-21, 2013. Abstract 869 р.
- Бацких С.Н. Безинтерфероновая терапия хронического гепатита С: смена препаратов или новая парадигма лечения? Рос. журн. гастроэнтерол., гепатол, колопроктол. 2014; (4): 23-31.
- Регистрационное удостоверение препарата Викейра Пак ЛП-002965 от 21.04.2015. grls.rosminzdrav.ru
- Российская инструкция по применению препарат Викейра Пак grls.rosminzdrav.ru
- SmPC от 09.03.2015 (Европейское агентство по оценке лекарственных средств). http://ec.europa.eu/health/documents/ community-register/2015/ 20150115130406/anx_130406_en.pdf
- Kumada H., Chayama K., Rodrigues L. Jr., Suzuki F., Ikeda K., Toyoda H., Sato K., Karino Y., Matsuzaki Y., Kioka K., Setze C., Pilot-Matias T., Patwardhan M., Vilchez R.A., Burroughs M., Redman R. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology 2015; 62(4): 1037-1046.